1. Salinomycin Derivatives Kill Breast Cancer Stem Cells by Lysosomal Iron Targeting.
- Author
-
Versini A, Colombeau L, Hienzsch A, Gaillet C, Retailleau P, Debieu S, Müller S, Cañeque T, and Rodriguez R
- Subjects
- Breast Neoplasms metabolism, Breast Neoplasms pathology, Female, Humans, Hyaluronan Receptors metabolism, Lysosomes metabolism, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells pathology, Pyrans chemistry, Breast Neoplasms drug therapy, Hyaluronan Receptors chemistry, Iron agonists, Lysosomes chemistry, Neoplastic Stem Cells chemistry, Pyrans pharmacology
- Abstract
Salinomycin (1) exhibits a large spectrum of biological activities including the capacity to selectively eradicate cancer stem cells (CSC), making it and its derivatives promising candidates for the development of drug leads against CSC. It has been previously shown that salinomycin and its C20-propargylamine derivative (Ironomycin (2)) accumulate in lysosomes and sequester iron in this organelle. Herein, a library of salinomycin derivatives is reported, including products of C20-amination, C1-esterification, C9-oxidation, and C28-dehydration. The biological activity of these compounds is evaluated against transformed human mammary epithelial HMLER CD24
low /CD44high cells, a well-established model of breast CSC, and HMLER CD24high /CD44low cells deprived of CSC properties. Unlike other structural alterations, derivative 4, which displays a cyclopropylamine at position C20, showed a strikingly low IC50 value of 23 nm against HMLER CD24low /CD44high cells. This study provides highly selective molecules to target the CSC niche, a potential interesting advance for drug development to prevent cancer resistance., (© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.)- Published
- 2020
- Full Text
- View/download PDF